委员李兆申:独角兽式医疗科技创新亟需政策支持

2018-03-08 佚名 环球网

中国大力鼓励医疗器械技术创新,医疗器械产业发展迅速,新技术层出不穷,相应政策的更新和匹配政策扮演着“助产士”的角色,从而使科技创新成果的尽快落地。对此,全国政协委员、中国工程院院士、中国医师协会内镜学会会长、海军军医大学附属长海医院消化科主任李兆申专门准备了“如何推动中国独角兽创新,推动健康领域的科技创新型企业发展”的提案。自主创新科技助力消化道肿瘤危机我国消化道肿瘤形势严峻,据李兆申介绍“消化道

中国大力鼓励医疗器械技术创新,医疗器械产业发展迅速,新技术层出不穷,相应政策的更新和匹配政策扮演着“助产士”的角色,从而使科技创新成果的尽快落地。对此,全国政协委员、中国工程院院士、中国医师协会内镜学会会长、海军军医大学附属长海医院消化科主任李兆申专门准备了“如何推动中国独角兽创新,推动健康领域的科技创新型企业发展”的提案。

自主创新科技助力消化道肿瘤危机

我国消化道肿瘤形势严峻,据李兆申介绍“消化道肿瘤病例占国内所有肿瘤病例近50%,其中85%左右的比例属于晚期病例。造成这一现状的原因是消化道肿瘤的早期诊断率极低”对此李兆申认为,只有尽早制订有效的消化道肿瘤筛查规范,发展适宜技术并尽快推广实施,才有机会降低中国晚期胃肠肿瘤的病例数量。

李兆申介绍,消化道肿瘤筛查应上升到“国家计划”,日本、韩国的早期消化道肿瘤诊断比例已经达到70%以上,而中国只有不到10%,差距太大。

中国已经诞生了专门用于提高肠胃疾病的诊断和初筛水平——特别是提高胃癌的早期发现率的磁控胶囊胃镜系统用于支撑我国消化道筛查计划。胶囊胃镜对胃部局灶性病变的诊断准确性与传统电子内镜一致,而检查舒适度明显高于传统电子内镜——受检者只要吞服一粒胶囊,15分钟左右即可完成检查。

据悉,安翰研发的胶囊内镜机器人是中国唯一,也是全球唯一,其高精度的磁场控制技术水平大幅领先于国际水平。多中心双盲对照临床研究显示,安翰胶囊内镜对胃部局灶性病变的诊断准确性与传统电子内镜高度一致。目前已经在全国近千家医疗机构进入临床应用。

自主研发科技应医保享受国民待遇

据统计,中国每年有1.2亿人需要进行胃镜检查,但内镜医师不足4万,巨大的医疗缺口造成绝大多数亟需做胃镜的患者无法得到检查,对胃镜的恐惧和排斥也是很多人不愿意接受检查的原因。现在,安翰胶囊胃镜作为我国在消化道领域原创性的重大突破,不仅打破了长久以来日系品牌在电子胃镜领域的垄断,更以其舒适安全准确以及便于操作的特性对我国消化道肿瘤筛查大有裨益。

但据记者了解,目前胶囊胃镜仅在上海被纳入医保,大量有需求的百姓因种种原因无法享受到此项科技福利。此前,中国著名的经济学家吴敬琏就曾在一个经济论坛中高度关注胶囊胃镜的普及问题,他认为,中国领先原创性重大突破产业项目,应享受国民待遇,纳入国家医保目录。

医保的推动作用是明显的:数据统计显示,在上海纳入医保后,上海市民对6个月内有4688人接受了胶囊胃镜检查,其中1152例(24.6%)受检者发现典型病变,溃疡7.62%,癌症的检出率达0.13%,结果触目惊心。这些人,幸运地实现了“早诊早治”。

将胶囊胃镜纳入医保,让患者自愿选择,在切实提高胃癌筛查效率,增进广大患者的医疗满意度的同时也可大量节省国家开支,减少医疗资源浪费。李兆申介绍,如果通过相应的政策,使我国胃早癌发现率提高到日本、韩国的平均水平,则我国每年降低晚期胃癌至少25万例,全国居民家庭每年少支出150亿,国家每年节省至少300亿元。

随着互联网技术的发展和普及,李兆申还建议,在推广类似胶囊胃镜等早筛手段时,可以尝试类似银行系统ATM 机布点的操作模式,打造磁控胶囊胃镜第三方图像采集中心,实现图像中心的覆盖区域从点拓展到面,再通过专家云阅片平台的大数据采集和分析,更好地满足我国公众的消化道检查需求,解决医护人员和医疗设备严重不足的问题。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1260317, encodeId=6871126031e7e, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285541, encodeId=54391285541d3, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536846, encodeId=a1de15368464e, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617640, encodeId=9dd9161e640d5, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294223, encodeId=7e9d294223c5, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 08 18:05:18 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-10 bioon3
  2. [GetPortalCommentsPageByObjectIdResponse(id=1260317, encodeId=6871126031e7e, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285541, encodeId=54391285541d3, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536846, encodeId=a1de15368464e, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617640, encodeId=9dd9161e640d5, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294223, encodeId=7e9d294223c5, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 08 18:05:18 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1260317, encodeId=6871126031e7e, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285541, encodeId=54391285541d3, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536846, encodeId=a1de15368464e, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617640, encodeId=9dd9161e640d5, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294223, encodeId=7e9d294223c5, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 08 18:05:18 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-10 mnda
  4. [GetPortalCommentsPageByObjectIdResponse(id=1260317, encodeId=6871126031e7e, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285541, encodeId=54391285541d3, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536846, encodeId=a1de15368464e, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617640, encodeId=9dd9161e640d5, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294223, encodeId=7e9d294223c5, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 08 18:05:18 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1260317, encodeId=6871126031e7e, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285541, encodeId=54391285541d3, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536846, encodeId=a1de15368464e, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617640, encodeId=9dd9161e640d5, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Sat Mar 10 08:58:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294223, encodeId=7e9d294223c5, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Mar 08 18:05:18 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

医疗信息化为什么难以实现

目睹医疗信息化的发展现状,我们不免感到失望。日常经验告诉我们,不管是想买一本书、预订餐厅、找喜欢的歌曲,还是导航到附近的星巴克,只须打开iPhone,下载一个应用程序,一切都能搞定。所以,我们也想当然地认为,开发医疗信息系统也将同样简单。或许,若苹果公司愿意研究、开发的话,可能早就实现了。然而,医疗信息化之路布满了大大小小的地雷。随着计算机逐步进入各科室和医学领域,这个与我们人类联系紧密的专业

互联网医疗:新事物当有新规制

日前,一家大型公立医院以收费方式开通网络在线医疗问诊服务,被一些人士认为是“为三甲公立医院正式进军互联网医疗拉开了帷幕”。笔者认为,这虽然是大势所趋,但每一步的挺近都不可忽视合法性操作和法律法规的配套与跟进,否则就免不了磕磕绊绊,甚至造成某种无序,付出不必要的学费。

世界日报:全美每年死于医疗疏失者逾25万人

美国《世界日报》日前刊文称,美国约翰霍普金斯大学一项研究指出,“医疗疏失”在美国人死因中排名第三,仅次于心脏病和癌症;每年死于医疗疏失的病患超过25万人,甚至可能多达44万人。专家呼吁通过改善医疗体制缺失,并提醒病患重视自身权利

十一部委联合整治虚假违法广告,突出医疗、药品等重点领域

日前,工商总局、中央宣传部、中央网信办、工业和信息化部、公安部、国家卫生计生委、中国人民银行、新闻出版广电总局、食品药品监管总局、银监会、国家中医药管理局等十一部委联合下发2018年整治虚假违法广告部际联席会议工作要点,进一步明确联席会议各成员单位的部门职责,并就落实工作提出具体要求。

做一个医疗工作中的侦察兵

儿科住院病人大多数是不会表达或表达不清楚的婴幼儿,俗称为“哑科”,这也是护理工作中判断病情的难点,而病情变化总会在身体上有一些病症表现,孩子不舒服时也会变得异常哭闹。患病时有冷、热、痛、痒表现,这些现象往往成为发现病症的线索,以便医护人员对症治疗、护理。冷症:临床上常常会发现婴幼儿体温过低或高热时的寒战,护士要通过观看、触摸,及时发现这些情况,随时测量体温,给予相应保暖措施。而注射退热针后常常会

杭州布局升级版智慧医疗 打通急救道路

2月27日,杭州市卫生和计划生育委员会发布《杭州市建设“智慧健康” 打造“智慧医疗升级版”三年行动计划(征求意见稿)》,在布局谋划“智慧健康”发展战略、打造“智慧医疗升级版”的这份行动计划中明确写道:2019年启动城市大脑医疗小脑建设工程;推进院前急救系统与市级全民健康信息平台的数据对接,推进与公安、交通、应急管理等相关部门的应急联动,实现与城市大脑数据对接,为急救病人提供更合理的调度、救治、转